Advances in the systemic therapy of malignant pleural mesothelioma (Q37070229)

18 August 2017

0 references

1 reference

title

Advances in the systemic therapy of malignant pleural mesothelioma (English)

1 reference

18 August 2017

1 reference

Dean A Fennell

1

1 reference

18 August 2017

Giovanni Gaudino

2

1 reference

18 August 2017

Kenneth J O'Byrne

3

1 reference

18 August 2017

Luciano Mutti

4

1 reference

18 August 2017

Jan van Meerbeeck

5

1 reference

18 August 2017

language of work or name

1 reference

1 March 2008

1 reference

Nature Clinical Practice Oncology

18 August 2017

1 reference

18 August 2017

5

1 reference

18 August 2017

136-147

1 reference

18 August 2017

3

1 reference

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature

18 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

The role of PET in the surgical management of malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Modeling of mesothelioma growth demonstrates weaknesses of current response criteria.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Phase II study of vinorelbine in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Can

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Biology and management of malignant pleural mesothelioma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Second-line treatment of malignant pleural mesothelioma with Pemetrexed (Alimta) -- a case report

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Phase II trial of ZD0473 as second-line therapy in mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Survival patterns for malignant mesothelioma: the SEER experience

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Positron emission tomography predicts survival in malignant pleural mesothelioma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Tumor angiogenesis and recurrence in stage I non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Angiogenesis is an independent prognostic factor in malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM)

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Expression of bcl-2 family members in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Using Gene Expression Ratios to Predict Outcome Among Patients With Mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Validation of genomics-based prognostic tests in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Gene expression profiles predict survival and progression of pleural mesothelioma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

New agents in the management of advanced mesothelioma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Inhibition of the met receptor in mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Induction of stem cell factor/c-Kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Sensitization of mesothelioma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by heat stress via the inhibition of the 3-phosphoinositide-dependent kinase 1/Akt pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

BCL-2 family regulation by the 20S proteasome inhibitor bortezomib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Mesothelin: a new target for immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Efficacy of CD40 ligand gene therapy in malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1039

7 January 2021

Identifiers

DOI

10.1038/NCPONC1039

1 reference

18 August 2017

1 reference